

prof. dr. Petra Denig, Professor Drug Utilisation Quality

## Employment

**Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)**

University of Groningen

1-Jan-2015 → present

## Research interests

Drug Utilisation Research and Pharmacoepidemiology, diabetes & cardiovascular treatment. Prescribing quality and indicators. Deprescribing. Medication adherence. Shared decision making and decision support tools.

## Activities

## Research output

**Man-vrouwverschillen in voorgeschreven medicatie bij DM2**

de Vries, S., Ambrož, M. & Denig, P., Sept-2023, In: Huisarts en Wetenschap. 66, p. 20-23 4 p.

**Process evaluation of a pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among adult people with type 2 diabetes**

Baas, G., Crutzen, S., Smits, S., Denig, P., Taxis, K. & Heringa, M., 10-Aug-2023, (E-pub ahead of print) In: Basic & clinical pharmacology & toxicology. 26 p.

**Community pharmacist-led interventions for patients with type 2 diabetes in low-income and middle-income countries: A scoping review**

Cahyaningsih, I., Lambert, M., Ochi, T., Li, F., Li, X., Denig, P. & Taxis, K., Aug-2023, In: Research in Social and Administrative Pharmacy. 19, 8, p. 1117-1130 14 p.

**Sex disparities in treatment patterns after metformin initiation among patients with type 2 diabetes mellitus**

Okora, M. P., de Vos, S., de Vries, S. T., Hak, E. & Denig, P., 31-Jul-2023, (E-pub ahead of print) In: Pharmacoepidemiology and Drug Safety. 11 p.

**Pharmacist-led intervention aimed at deprescribing and appropriate use of cardiometabolic medication among people with type 2 diabetes**

Crutzen, S., Baas, G., Denig, P., Heringa, M. & Taxis, K., May-2023, In: Research in Social and Administrative Pharmacy. 19, 5, 10 p.

**Letter to the Editor: a Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications**

Stuijt, P. J. C., Taxis, K. & Denig, P., Apr-2023, In: Journal of General Internal Medicine. 38, 5, p. 1316 1 p.

**Role of Serum Lipids, Blood Glucose and Blood Pressure in Breast Cancer Risk for Women with Type 2 Diabetes Mellitus**

Zhang, F., de Bock, G. H., Denig, P., Landman, G. W., Zhang, Q. & Sidorenkov, G., 24-Jan-2023, In: Clinical epidemiology. 15, p. 109-121 13 p.

**Attitudes towards deprescribing and patient-related factors associated with willingness to stop medication among older patients with type 2 diabetes (T2D) in Indonesia: a cross-sectional survey study**

Okora, M. P., Yuniar, C. T., Amalia, L., Abdulah, R., Hak, E. & Denig, P., 12-Jan-2023, In: BMC Geriatrics. 23, 1, 11 p.

**Sex disparities in medication prescribing amongst patients with type 2 diabetes mellitus managed in primary care**

Ambrož, M., Geelink, M., Smits, K. P. J., de Vries, S. T. & Denig, P., Jan-2023, In: Diabetic Medicine. 40, 1, 10 p., e14987.

**Praat met oudere over minderen van medicatie**

Denig, P., Taxis, K., Heringa, M., van Dijk, L. & Stuijt, P., 9-Dec-2022, In: Pharmaceutisch Weekblad. 49

**Factors Influencing Preferences and Responses Towards Drug Safety Communications: A Conjoint Experiment Among Hospital-Based Healthcare Professionals in the Netherlands**

de Vries, E., Bakker, E., Monster, T. B. M., Denig, P. & Mol, P. G. M., Nov-2022, In: Drug Safety. 45, p. 1369-1380 12 p.

**Erratum to: Precision medicine approaches for diabetic kidney disease: opportunities and challenges**

Tye, S. C., Denig, P. & Heerspink, H. J. L., Jun-2022, In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 37, 6, 1 p., gfab296.

**Less Timely Initiation of Glucose-Lowering Medication Among Younger and Male Patients With Diabetes and Similar Initiation of Blood Pressure-Lowering Medication Across Age and Sex: Trends Between 2015 and 2020**

Ambrož, M., de Vries, S. T., Hoogenberg, K. & Denig, P., 12-May-2022, In: Frontiers in Pharmacology. 13, 10 p., 883103.

**Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers**

Tye, S. C., de Vries, S. T., Mann, J. F. E., Schechter, M., Mosenzon, O., Denig, P. & Heerspink, H. J. L., 13-Apr-2022, In: Frontiers in Pharmacology. 13, 10 p., 786767.

**Barriers and Enablers of Healthcare Providers to Deprescribe Cardiometabolic Medication in Older Patients: A Focus Group Study**

Abou, J., Crutzen, S., Tromp, V., Heringa, M., Van Marum, R., Elders, P., Taxis, K., Denig, P. & Hugtenburg, J., Mar-2022, In: Drugs & Aging. 39, 3, p. 209-221 13 p.

**Differences in Older Patients' Attitudes Toward Deprescribing at Contextual and Individual Level**

Okora, M. P., Edwina, A. E. & Denig, P., 11-Feb-2022, In: Frontiers in public health. 10, 7 p., 795043.

**Prediction of the Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Based on Short-Term Changes in Multiple Risk Markers**

Tye, S. C., de Vries, S. T., Wanner, C., Denig, P. & Heerspink, H., 25-Jan-2022, In: Frontiers in Pharmacology. 12, 10 p., 786706.

**Handling of New Drug Safety Information in the Dutch Hospital Setting: A Mixed Methods Approach**

de Vries, E., Bakker, E., Francisca, R. D. C., Croonen, S., Denig, P. & Mol, P. G. M., 2022, In: Drug Safety. 45, 4, p. 369-378 10 p.

**Emotional Distress is Associated with Lower Health-Related Quality of Life Among Patients with Diabetes Using Antihypertensive and/or Antihyperlipidemic Medications: A Multicenter Study in Indonesia**

Alfian, S. D., Annisa, N., Iskandarsyah, A., Perwitasari, D. A., Denig, P., Hak, E. & Abdulah, R., 7-Dec-2021, In: Therapeutics and clinical risk management. 17, p. 1333-1342 10 p.

**Identifying patients at increased risk of hypoglycaemia in primary care: Development of a machine learning-based screening tool**

Crutzen, S., Nagaraj, S. B., Taxis, K. & Denig, P., Oct-2021, In: Diabetes-Metabolism research and reviews. 37, 7, 10 p., e3426.

**Older Age, Polypharmacy, and Low Systolic Blood Pressure Are Associated With More Hypotension-Related Adverse Events in Patients With Type 2 Diabetes Treated With Antihypertensives**

Ambrož, M., de Vries, S., Hoogenberg, K. & Denig, P., 24-Sept-2021, In: Frontiers in Pharmacology. p. 1-8 8 p.

**Motives to Report Adverse Drug Reactions to the National Agency: A Survey Study among Healthcare Professionals and Patients in Croatia, The Netherlands, and the UK**

de Vries, S. T., Denig, P., Andrić, A., Dimov Di Giusti, M., Ptaszynska-Neophytou, A., Härmark, L., Mol, P. G. M. & the IMI Web-RADR Work Package 3b Consortium and SCOPE Joint Action Work Package, 8-Aug-2021, In: Drug Safety. 11 p.

**Motives to report adverse drug reactions to the national agency: A survey study among healthcare professionals and patients in Croatia, the Netherlands, and the UK**

de Vries, S. T., Denig, P., Andric, A., Di Giusti, M. D., Ptaszynska-Neophytou, A., Harmark, L. & Mol, P. G. M., Aug-2021, In: Pharmacoepidemiology and Drug Safety. 30, p. 277-277 1 p.

**Trends in polypharmacy and potentially inappropriate medication (PIM) in older and middle-aged people treated for diabetes**

Oktora, M. P., Alfian, S. D., Bos, H. J., Schuiling-Veninga, C. C. M., Taxis, K., Hak, E. & Denig, P., Jul-2021, In: British Journal of Clinical Pharmacology. 87, 7, p. 2807-2817 11 p.

**Precision medicine approaches for diabetic kidney disease: opportunities and challenges**

Tye, S. C., Denig, P. & Heerspink, H. J. L., 22-Jun-2021, In: Nephrology, Dialysis, Transplantation. 36, Supplement\_2, p. 3-9 7 p.

**Older people's attitudes towards deprescribing cardiometabolic medication**

Crutzen, S., Abou, J., Smits, S. E., Baas, G., Hugtenburg, J. G., Heringa, M., Denig, P. & Taxis, K., 16-Jun-2021, In: BMC Geriatrics. 21, 1, 12 p., 366.

**Type 2 diabetes patients' views on prevention of hypoglycaemia - a mixed methods study investigating self-management issues and self-identified causes of hypoglycaemia**

Crutzen, S., van den Born-Bondt, T., Denig, P. & Taxis, K., 14-Jun-2021, In: BMC Family Practice. 22, 1, 13 p., 114.

**Glycemic Control for Colorectal Cancer Survivors Compared to Those without Cancer in the Dutch Primary Care for Type 2 Diabetes: A Prospective Cohort Study**

de Haan-Du, J., Landman, G. W. D., Kleefstra, N., Schrijnders, D., Manders, M., Bos, A. C. R. K., Tromp-van Driel, C., Denig, P., Groenier, K. H. & de Bock, G. H., 2-Jun-2021, In: Cancers. 13, 11, 10 p., 2767.

**Process Evaluation of Implementing a Pharmacist-Led Intervention to Improve Adherence to Antihypertensive Drugs Among Patients with Type 2 Diabetes in Indonesian Community Health Centers**

Alfian, S. D., van Boven, J. F. M., Iskandarsyah, A., Abdulah, R., Hak, E. & Denig, P., May-2021, In: Frontiers in Pharmacology. 12, 9 p., 652018.

**Sex Differences in Lipid Profile across the Life Span in Patients with Type 2 Diabetes: A Primary Care-Based Study**

Ambrož, M., de Vries, S., Vart, P., Dullaart, R., Roeters van Lennep, J. E., Denig, P. & Hoogenberg, K., 19-Apr-2021, In: Journal of Clinical Medicine. 10, 8, 12 p., 1775.

**Effectiveness of a targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: a cluster randomised controlled trial**

Alfian, S. D., van Boven, J. F. M., Abdulah, R., Sukandar, H., Denig, P. & Hak, E., 2-Apr-2021, In: British Journal of Clinical Pharmacology. 87, 4, p. 2032-2042 11 p.

**Medicatie minderen bij ouderen: Waarom wel of niet?**

Denig, P., Edelman, M. & Taxis, K., 9-Feb-2021, In: Nederlands Tijdschrift voor Geneeskunde. 165, 5 p., D4728.

**Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review**

Oktora, M. P., Kerr, K. P., Hak, E. & Denig, P., 1-Feb-2021, In: Diabetic Medicine. 38, 2, 13 p., 14408.

**Targeted and tailored pharmacist-led intervention improved adherence to antihypertensive drugs**

Alfian, S. D., van Boven, J. F. M., Abdulah, R., Sukandar, H., Denig, P. & Hak, E., Feb-2021, In: International Journal of Clinical Pharmacy. 43, 1, p. 288-288 1 p.

**Trends in HbA1c thresholds for initiation of hypoglycemic agents: Impact of changed recommendations for older and frail patients**

Ambroz, M., Vries, de, S., Hoogenberg, K. & Denig, P., Jan-2021, In: Pharmacoepidemiology and Drug Safety. 30, 1, p. 37-44 8 p.

**Changes in blood pressure thresholds for initiating antihypertensive medication in patients with diabetes: a repeated cross-sectional study focusing on the impact of age and frailty**

Ambroz, M., Vries, de, S., Sidorenkov, G., Hoogenberg, K. & Denig, P., 10-Sept-2020, In: *BMJ Open*. 10, 9, p. 1-8 8 p., e037694.

**Barriers and Enablers of Older Patients to Deprescribing of Cardiometabolic Medication: A Focus Group Study**

Crutzen, S., Baas, G., Abou, J., van den Born-Bondt, T., Hugtenburg, J. G., Bouvy, M. L., Heringa, M., Taxis, K. & Denig, P., 20-Aug-2020, In: *Frontiers in Pharmacology*. 11, 11 p., 1268.

**Correction to: Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study**

SCOPE Work Package 6, de Vries, S. T., van der Sar, M. J. M., Coleman, A. M., Escudero, Y., Rodríguez Pascual, A., Maciá Martínez, M-Á., Cupelli, A., Baldelli, I., Šipić, I., Andrić, A., Michan, L., Denig, P. & Mol, P. G. M., 1-Aug-2020, In: *Drug Safety*. 43, 8, p. 827-829 3 p.

**Drug Safety Issues Covered by Lay Media: A Cohort Study of Direct Healthcare Provider Communications Sent between 2001 and 2015 in The Netherlands**

de Vries, E., Denig, P., de Vries, S. T., Monster, T. B. M., Hugtenburg, J. G. & Mol, P. G. M., Jul-2020, In: *Drug Safety*. 43, 7, p. 677-690 14 p.

**Sex Differences in Adverse Drug Reactions of Metformin: A Longitudinal Survey Study**

de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M. & van Puijenbroek, E. P., May-2020, In: *Drug Safety*. 43, 5, p. 489-495 7 p.

**Modifiable Factors Associated with Non-adherence to Antihypertensive or Antihyperlipidemic Drugs Are Dissimilar: a Multicenter Study Among Patients with Diabetes in Indonesia**

Alfian, S. D., Annisa, N., Fajriansyah, F., Perwitasari, D. A., Abdulah, R., Hak, E. & Denig, P., 16-Apr-2020, In: *Journal of General Internal Medicine*. 35, 10, p. 2897-2906 10 p.

**Long-term exposure to anticholinergic and sedative medications and cognitive and physical function in later life**

Wouters, H., Hilmer, S. N., Gnjjidic, D., Van Campen, J. P., Teichert, M., Van Der Meer, H. G., Schaap, L. A., Huisman, M., Comijs, H. C., Denig, P., Lamoth, C. J. & Taxis, K., Feb-2020, In: *Journal of Gerontology: Medical sciences*. 75, 2, p. 357-365 9 p.

**Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: Study protocol of a cluster randomised controlled trial**

Alfian, S. D., Abdulah, R., Denig, P., van Boven, J. F. M. & Hak, E., Jan-2020, In: *BMJ Open*. 10, 1, 8 p., e034507.

**Population-based screen-detected type 2 diabetes mellitus is associated with less need for insulin therapy after 10 years**

Vos, R. C., den Ouden, H., Daamen, L. A., Bilo, H. J. G., Denig, P. & Rutten, G. E. H. M., 2020, In: *BMJ Open Diabetes Research & Care*. 8, 1, 7 p., 000949.

**Patients' Attitudes Towards Deprescribing Alpha-Blockers and Their Willingness to Participate in a Discontinuation Trial**

Edelman, M., Jellema, P., Hak, E., Denig, P. & Blanker, M. H., Dec-2019, In: *Drugs & Aging*. 36, 12, p. 1133-1139 7 p.

**Pharmacy-based predictors of non-adherence, non-persistence and reinitiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands**

Alfian, S. D., Denig, P., Coelho, A. & Hak, E., 15-Nov-2019, In: *PLoS ONE*. 14, 11, 14 p., e0225390.

**No significant association of type 2 diabetes-related genetic risk scores with glycosylated haemoglobin levels after initiating metformin or sulphonylurea derivatives**

Martono, D. P., Heerspink, H. J. L., Hak, E., Denig, P. & Wilffert, B., Oct-2019, In: *Diabetes obesity & metabolism*. 21, 10, p. 2267-2273 7 p.

**Adverse drug event patterns experienced by patients with diabetes: A diary study in primary care**

Denig, P., van Puijenbroek, E. P., Soliman, N., Mol, P. G. M. & de Vries, S. T., Sept-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, 9, p. 1175-1179 5 p.

**When drug treatments bias genetic studies: Mediation and interaction**

Schmidt, A. F., Heerspink, H. J. L., Denig, P., Finan, C. & Groenwold, R. H. H., 28-Aug-2019, In: *PLoS ONE*. 14, 8, 17 p., 0221209.

**Determinants for safety issue coverage by lay and social media**

de Vries, E., Denig, P., de Vries, S. T., Monster, T. B. M., Hugtenburg, J. G. & Mol, P. G. M., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 244-245 2 p.

**Emerging solutions to addressing challenges in measuring adherence to multiple medications**

Lauffenburger, J., Walsh, C., Sinnott, S-J., Franklin, J. & Denig, P., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 415-416 2 p.

**Gender differences in reported adverse drug reactions at different time periods after drug initiation**

de Vries, S. T., Denig, P., Mol, P. G. M. & van Puijenbroek, E. P., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 516-517 2 p.

**Identifying type 2 diabetes patients at risk for hypoglycemic events: Dealing with class imbalance**

Crutzen, S., Nagaraj, S. B., Taxis, K. & Denig, P., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 569 1 p.

**Pharmacy-based predictors of non-adherence, non-persistence, and re-initiation of antihypertensive drugs among patients on oral diabetes drugs in the Netherlands**

Alfian, S. D., Denig, P., Coelho, A. & Hak, E., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 425-425 1 p.

**Prescribing quality in secondary care patients with different stages of chronic kidney disease: a retrospective study in the Netherlands**

Smits, K. P., Sidorenkov, G., van Ittersum, F. J., Waanders, F., Bilo, H. J., Navis, G. J. & Denig, P., Aug-2019, In: *BMJ Open*. 9, 7, 9 p., e025784.

**Sex differences in Cardiometabolic treatment among patients with type 2 diabetes**

Denig, P., Vries, D. S. T., Puijenbroek, V. E. & Mol, P. G. M., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 142-142 1 p.

**Trends in blood pressure thresholds for initiation of antihypertensive treatment in patients with type 2 diabetes**

Ambroz, M., deVries, S. T., Sidorenkov, G., Hoogenberg, K. & Denig, P., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 396-397 2 p.

**Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States**

Oktora, M. P., Denig, P., Bos, J. H. J., Schuilting-Veninga, C. C. M. & Hak, E., Aug-2019, In: *Pharmacoepidemiology and Drug Safety*. 28, p. 533-534 2 p.

**Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study**

de Vries, S. T., Denig, P., Ekhart, C., Burgers, J. S., Kleefstra, N., Mol, P. G. M. & van Puijenbroek, E. P., Jul-2019, In: *British Journal of Clinical Pharmacology*. 85, 7, p. 1507-1515 9 p.

**Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form: A Database Study**

de Vries, S. T., Harrison, J., Revelle, P., Ptaszynska-Neophytou, A., Radecka, A., Ragunathan, G., Tregunno, P., Denig, P. & Mol, P. G. M., Jul-2019, In: *Drug Safety*. 42, 7, p. 881-886 6 p.

**A systematic review finds inconsistency in the measures used to estimate adherence and persistence to multiple cardiometabolic medications**

Alfian, S. D., Pradipta, I. S., Hak, E. & Denig, P., Apr-2019, In: Journal of Clinical Epidemiology. 108, p. 44-53 10 p.

**Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States**

Okora, M. P., Denig, P., Bos, J. H. J., Schuiling-Veninga, C. C. M. & Hak, E., 22-Mar-2019, In: PLoS ONE. 14, 3, e0214240.

**Development and Piloting of an Algorithm to Select Older Patients for Different Types of Medication Review**

Crutzen, S., Schuling, J., Hugtenburg, J. G., Verduijn, M., Teichert, M., Taxis, K. & Denig, P., 19-Mar-2019, In: Frontiers in Pharmacology. 10, 9 p., 217.

**Predicting Short-term and Long-term HbA1c Response after Insulin Initiation in Patients with Type 2 Diabetes Mellitus using Machine Learning**

Nagaraj, S. B., Sidorenkov, G., van Boven, J. F. M. & Denig, P., 2019, In: Diabetes obesity & metabolism. 21, p. 2704-2711 8 p.

**Gender differences in adverse drug reaction reports; How can they be explained?**

De Vries, S., Van Puijenbroek, E., Mol, P., Ekhart, C. & Denig, P., 1-Nov-2018, p. 1142. 1 p.

**Population based diabetes screening is associated with less insulin therapy compared to usual care**

Vos, R. C., den Ouden, H., Daamen, L. A., Bilo, H. J. G., Denig, P. & Rutten, G. E. H., Oct-2018, In: Diabetologia. 61, p. S424 1 p.

**Is guideline-adherent prescribing associated with quality of life in patients with type 2 diabetes?**

Smits, K. P. J., Sidorenkov, G., Kleefstra, N., Hendriks, S. H., Bouma, M., Meulepas, M., Navis, G., Bilo, H. J. G. & Denig, P., 16-Aug-2018, In: PLoS ONE. 13, 8, 13 p., e0202319.

**A systematic review of measures for calculating adherence and persistence to multiple medication from prescription data**

Alfian, S. D., Pradipta, I. S., Hak, E. & Denig, P., Aug-2018, In: Pharmacoepidemiology and Drug Safety. 27, 52, p. 119-120 2 p.

**Efficient selection of older patients for medication review: Development and validation of a selection algorithm**

ESOM Grp, Aug-2018, In: Pharmacoepidemiology and Drug Safety. 27, p. 506 1 p.

**Gender differences in drug-Adverse drug reaction combinations reported to the national pharmacovigilance centre in the Netherlands**

de Vries, S. T., Denig, P., Ekhart, C., Mol, P. G. M. & van Puijenbroek, E. P., Aug-2018, In: Pharmacoepidemiology and Drug Safety. 27, p. 256 1 p.

**HbA1c response after insulin initiation in patients with type 2 diabetes mellitus in real life practice: Identifying distinct subgroups**

Sidorenkov, G., van Boven, J. F. M., Hoekstra, T., Nijpels, G., Hoogenberg, K. & Denig, P., Aug-2018, In: Diabetes obesity & metabolism. 20, 8, p. 1957-1964 8 p.

**Interest in a mobile app for two-way risk communication-A survey study among European health care professionals and patients**

de Vries, S. T., Denig, P. & Mol, P. G. M., Aug-2018, In: Pharmacoepidemiology and Drug Safety. 27, p. 257 1 p.

**Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients**

de Vries, S. T., Denig, P., Lasheras Ruiz, C., Houyez, F., Wong, L., Sutcliffe, A., Mol, P. G. M. & IMI Web-RADR Work Package 3b Consortium, Jul-2018, In: Drug Safety. 41, 7, p. 697-712 16 p.

**Non-LDL dyslipidemia is prevalent in the young and determined by lifestyle factors and age: The LifeLines cohort**  
de Vries, J. K., Balder, J. W., Pena, M. J., Denig, P. & Smit, A. J., Jul-2018, In: *ATHEROSCLEROSIS*. 274, p. 191-198 8 p.

**Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study**  
SCOPE Work Package 6, Jul-2018, In: *Drug Safety*. 41, 7, p. 713-724 12 p.

**Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study**  
Apperloo, E. M., Pena, M. J., de Zeeuw, D., Denig, P. & Heerspink, H., Jun-2018, In: *Diabetes obesity & metabolism*. 20, 6, p. 1377-1383 7 p.

**Added value of diabetes risk genes to the prediction of HbA1c levels in patients initiating metformine or sulfonylurea derivatives. German Pharm-Tox Summit, Göttingen**  
Martono, D., Heerspink, H., Hak, E., Denig, P. & Wilffert, B., Feb-2018, In: *Naunyn-Schmiedeberg's Archives of Pharmacology*. 391, Supplement 1, p. S15 1 p., 55.

**Views of general practice staff about the use of a patient-oriented treatment decision aid in shared decision making for patients with type 2 diabetes: A mixed-methods study**  
Wildeboer, A., du Pon, E., Schuling, J., Haaijer-Ruskamp, F. M. & Denig, P., Feb-2018, In: *Health Expectations*. 21, 1, p. 64-74 11 p.

**FTO-werkmateriaal: Diabetes mellitus type 2: Module DM2 en patiëntspecifieke voorschrijfindicator**  
Denig, P., Jan-2018

**Medicatiebeoordelingen voorzien in behoefte patiënt: Apotheker wordt beter zichtbaar voor medicijngebruiker**  
Crutzen, S., Marijnissen, B., Taxis, K. & Denig, P., 2018, In: *Pharmaceutisch Weekblad*. 153, p. 8-9

**Pharmacy-based predictors of non-persistence with and non-adherence to statin treatment among patients on oral diabetes medication in the Netherlands**  
Alfian, S. D., Worawutputtpong, P., Schuling-Veninga, C. C. M., van der Schans, J., Bos, JH., Hak, E. & Denig, P., 2018, In: *Current Medical Research and Opinion*. 34, 6, p. 1013-1019 7 p.

**Application of the STOPP/START criteria to a medical record database**  
Nauta, K. J., Groenhof, F., Schuling, J., Hugtenburg, J. G., van Hout, H. P. J., Haaijer-Ruskamp, F. M. & Denig, P., Oct-2017, In: *Pharmacoepidemiology and Drug Safety*. 26, 10, p. 1242-1247 6 p.

**Long-term exposure to anticholinergic and sedative drugs and cognitive and physical function in later life**  
Wouters, H., Hilmer, S., Gnjjidic, D., Van Campen, J., Teichert, M., Van Der Meer, H., Schaap, L., Huisman, M., Denig, P., Lamoth, C. & Taxis, K., 1-Sept-2017, In: *European Geriatric Medicine*. 8, p. 19 1 p.

**Trajectories of long-term exposure to anticholinergic and sedative drugs: A latent class growth analysis**  
Wouters, H., Hilmer, S., Van Campen, J., Van Der Meer, H., Gardarsdottir, H., Schaap, L., Huisman, M., Denig, P., Taxis, K. & Rhebergen, D., 1-Sept-2017, In: *European Geriatric Medicine*. 8, p. 21 1 p.

**Predictors of non-adherence to and non-persistence with statin therapy among patients on oral diabetes medication in the Netherlands: A retrospective inception cohort study**  
Alfian, S. D., Worawutputtpong, P., Schuling-Veninga, C. C. M., Van Der Schans, J., Bos, JH., Hak, E. & Denig, P., 22-Aug-2017, In: *Pharmacoepidemiology and Drug Safety*. 26, Supplement 2, p. 517-518 2 p., 856.

**Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences**  
de Vries, S. T., van der Sar, M. J. M., Cupelli, A., Baldelli, I., Coleman, A. M., Montero, D., Sipic, I., Andric, A., Wennberg, A., Ahlqvist-Rastad, J., Denig, P., Mol, P. G. M. & SCOPE Work Package 6, Aug-2017, In: *Drug Safety*. 40, 8, p. 729-742

14 p.

**Patient attitudes towards deprescribing of alpha-blockers and willingness to participate in a discontinuation trial**

Edelman, M., Blanker, M., Jellema, P., Hak, E. & Denig, P., 1-Jul-2017, In: *Neurourology and urodynamics*. 36, p. 242-244 3 p.

**Prescribing Quality and Prediction of Clinical Outcomes in Patients With Type 2 Diabetes: A Prospective Cohort Study**

Smits, K. P. J., Sidorenkov, G., Navis, G., Bouma, M., Meulepas, M. A., Bilo, H. J. G. & Denig, P., 1-Jul-2017, In: *Diabetes Care*. 40, 7, p. E83-E84 2 p.

**Outcome prioritisation tool for medication review in older patients with multimorbidity: a pilot study in general practice**

van Summeren, J. J., Schuling, J., Haaijer-Ruskamp, F. M. & Denig, P., Jul-2017, In: *British Journal of General Practice*. 67, 660, p. E501-E506 6 p.

**Development and validation of prescribing quality indicators for patients with type 2 diabetes**

Smits, K. P. J., Sidorenkov, G., Kleefstra, N., Bouma, M., Meulepas, M., Voorham, J., Navis, G., Bilo, H. J. G. & Denig, P., Jan-2017, In: *International Journal of Clinical Practice*. 71, 1, 10 p., e12922.

**Determinants for healthcare professionals to take action on Direct Healthcare Professional Communications (DHPCs)**

de Vries, S., Denig, P. & Mol, P. G. M., 2017.

**Predictors of HbA1c levels in patients initiating metformin**

Martono, D. P., Hak, E., Lambers Heerspink, H., Wilffert, B. & Denig, P., Dec-2016, In: *Current Medical Research and Opinion*. 32, 12, p. 2021-2028 8 p.

**The Ethics of Deprescribing in Older Adults**

Reeve, E., Denig, P., Hilmer, S. N. & ter Meulen, R., Dec-2016, In: *Journal of bioethical inquiry*. 13, 4, p. 581-590 10 p.

**Development and initial validation of prescribing quality indicators for patients with chronic kidney disease**

Smits, K. P. J., Sidorenkov, G., Bilo, H. J. G., Bouma, M., van Ittersum, F. J., Voorham, J., Navis, G. & Denig, P., 11-Nov-2016, In: *Nephrology, Dialysis, Transplantation*. 31, 11, p. 1876-1886 11 p.

**Role of Patient and Practice Characteristics in Variance of Treatment Quality in Type 2 Diabetes between General Practices**

Cho, Y. Y., Sidorenkov, G. & Denig, P., 2-Nov-2016, In: *PLoS ONE*. 11, 11, 13 p., e0166012.

**Bijdrage ZonMw onderzoek aan kwaliteitscyclus Chronisch Nierfalen**

Denig, P., Nov-2016

**Process quality indicators for chronic kidney disease risk management: a systematic literature review**

Smits, K. P. J., Sidorenkov, G., Bilo, H. J. G., Bouma, M., Navis, G. J. & Denig, P., Oct-2016, In: *International Journal of Clinical Practice*. 70, 10, p. 861-869 9 p.

**Prescribing patterns, adherence and LDL-cholesterol response of type 2 diabetes patients initiating statin on low-dose versus standard-dose treatment: a descriptive study**

de Vries, F. M., Voorham, J., Hak, E. & Denig, P., Jun-2016, In: *International Journal of Clinical Practice*. 70, 6, p. 482-492 11 p.

**Identification of major cardiovascular events in patients with diabetes using primary care data**

Pouwels, K. B., Voorham, J., Hak, E. & Denig, P., 2-Apr-2016, In: *BMC Health Services Research*. 16, 8 p., 110.

**Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients**

de Vries, F. M., Voorham, J., Hak, E. & Denig, P., 2-Dec-2015, In: *Current Medical Research and Opinion*. 31, 12, p. 2197-2206 10 p.



**The Role of Patients' Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes**

de Vries, S. T., de Vries, F. M., Dekker, T., Haaijer-Ruskamp, F. M., de Zeeuw, D., Ranchor, A. V. & Denig, P., 7-Oct-2015, In: PLoS ONE. 10, 10, 15 p., e0139755.

**Predictors of response in initial users of metformin and sulphonylurea derivatives: A systematic review**

Martono, D. P., Lub, R., Heerspink, H. J. L., Hak, E., Wilffert, B. & Denig, P., Jul-2015, In: Diabetic Medicine. 32, 7, p. 853-864 12 p.

**Understanding drug preferences, different perspectives**

Mol, P. G. M., Arnardottir, A. H., Straus, S. M. J., de Graeff, P. A., Haaijer-Ruskamp, F. M., Quik, E. H., Krabbe, P. F. M. & Denig, P., Jun-2015, In: British Journal of Clinical Pharmacology. 79, 6, p. 978-987 10 p.

**Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design**

de Vries, F. M., Denig, P., Vegter, S., Bos, H. J., Postma, M. J. & Hak, E., Apr-2015, In: Current Medical Research and Opinion. 31, 4, p. 595-602 8 p.

**Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: A meta-analysis**

De Vries, F. M., Kolthof, J., Postma, M. J., Denig, P. & Hak, E., 5-Nov-2014, In: PLoS ONE. 9, 11, 8 p., e111247.

**The validity of a patient-reported adverse drug event questionnaire using different recall periods**

de Vries, S. T., Haaijer-Ruskamp, F. M., de Zeeuw, D. & Denig, P., Nov-2014, In: Quality of Life Research. 23, 9, p. 2439-2445 7 p.

**Does a cardiovascular event change adherence to statin treatment in patients with type 2 diabetes? A matched cohort design**

De Vries, D., Denig, P., Vegter, S., Bos, H. J., Postma, M. J. & Hak, E., 1-Oct-2014, In: Pharmacoepidemiology and Drug Safety. 23, S1, p. 319-320 2 p.

**Statin adherence and treatment LDL-cholesterol response in type 2 diabetes patients**

De Vries, D., Voorham, J., Hak, E. & Denig, P., 1-Oct-2014, In: Pharmacoepidemiology and Drug Safety. 23, S1, p. 322-323 2 p.

**Statin Adherence and Treatment LDL-Cholesterol Response in Type 2 Diabetes Patients**

de Vries, D., Voorham, J., Hak, E. & Denig, P., Oct-2014, In: Pharmacoepidemiology and Drug Safety. 23, p. 322-323 2 p.

**Effects of a patient oriented decision aid for prioritising treatment goals in diabetes: pragmatic randomised controlled trial**

Denig, P., Schuling, J., Haaijer-Ruskamp, F. & Voorham, J., 25-Sept-2014, In: BMJ (Clinical research ed.). 349, 14 p., 5651.

**Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study**

de Vries, S. T., Haaijer-Ruskamp, F. M., de Zeeuw, D. & Denig, P., 13-Aug-2014, In: Health and Quality of Life Outcomes. 12, 9 p., 103.

**Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with diabetes**

de Vries, S. T., Keers, J. C., Visser, R., De Zeeuw, D., Haaijer-Ruskamp, F. M., Voorham, J. & Denig, P., Aug-2014, In: International Journal of Behavioral Medicine. 21, p. S202-S202 1 p.

**Potential Overtreatment and Undertreatment of Diabetes in Different Patient Age Groups in Primary Care After the Introduction of Performance Measures**

de Vries, S. T., Voorham, J., Haaijer-Ruskamp, F. M. & Denig, P., May-2014, In: Diabetes Care. 37, 5, p. 1312-1320 9 p.

**New renal guidelines; is more better?**

Denig, P. & de Zeeuw, D., Apr-2014, In: Nephrology, Dialysis, Transplantation. 29, 4, p. 720-721 2 p.

**Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands**

de Vries, F. M., Denig, P., Visser, S. T., Hak, E. & Postma, M. J., Mar-2014, In: Value in Health. 17, 2, p. 223-230 8 p.

**Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes**

de Vries, S. T., Keers, J. C., Visser, R., de Zeeuw, D., Haaijer-Ruskamp, F. M., Voorham, J. & Denig, P., Feb-2014, In: Journal of Psychosomatic Research. 76, 2, p. 134-138 5 p.

**Effects of the occurrence of a first cardiovascular event on statin adherence in type 2 diabetes: A matched cohort design**

De Vries, F. M., Denig, P., Vegter, S., Bos, H. J., Postma, M. J. & Hak, E., 1-Nov-2013, In: Value in Health. 16, 7, p. 532-533 2 p.

**Post-Approval Safety Issues with Innovative Drugs: A European Cohort Study**

Mol, P. G. M., Arnardottir, A. H., Motola, D., Vrijlandt, P. J., Duijnhoven, R. G., Haaijer-Ruskamp, F. M., de Graeff, P. A., Denig, P. & Straus, S. M. J. M., Nov-2013, In: Drug Safety. 36, 11, p. 1105-1115 11 p.

**Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?**

Sidorenkov, G., Voorham, J., de Zeeuw, D., Haaijer-Ruskamp, F. M. & Denig, P., 30-Oct-2013, In: PLoS ONE. 8, 10, 8 p., e78821.

**Cost-effectiveness of statins for primary prevention in newly diagnosed type 2 diabetes patients: An illustration for The Netherlands**

De Vries, F. M., Denig, P., Visser, S. T., Hak, E. & Postma, M. J., Oct-2013, In: Pharmacoepidemiology and Drug Safety. 22, s1, p. 117-118 2 p.

**Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database**

Sidorenkov, G., Voorham, J., de Zeeuw, D., Haaijer-Ruskamp, F. M. & Denig, P., Apr-2013, In: BMJ Quality & Safety. 22, 4, p. 339-347 9 p.

**Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort**

Hellemons, M. E., Denig, P., Voorham, J., Heerspink, H. J. L. & de Zeeuw, D., Mar-2013, In: Nephrology Dialysis Transplantation. 28, 3, p. 706-715 10 p.

**Representativeness of diabetes patients participating in a web-based adverse drug reaction monitoring system**

Harmark, L., Alberts, S., van Puijenbroek, E., Denig, P. & van Grootheest, K., Mar-2013, In: Pharmacoepidemiology and Drug Safety. 22, 3, p. 250-255 6 p.

**Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort**

Sidorenkov, G., Voorham, J., Haaijer-Ruskamp, F. M., de Zeeuw, D. & Denig, P., Feb-2013, In: Medical Care. 51, 2, p. 172-179 8 p.

**Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire**

de Vries, S. T., Mol, P. G. M., de Zeeuw, D., Haaijer-Ruskamp, F. M. & Denig, P., 2013, In: Drug Safety. 36, 9, p. 765-777 13 p.

**The effect of a patient-oriented treatment decision aid for risk factor management in patients with diabetes (PORTDA-diab): Study protocol for a randomised controlled trial**

Denig, P., Dun, M., Schuling, J., Haaijer-Ruskamp, F. M. & Voorham, J., 21-Nov-2012, In: Trials. 13, p. 219- 12 p., 219.

**Development of a minimal set of prescribing quality indicators for diabetes management on a general practice level**  
Martirosyan, L., Haaijer-Ruskamp, F. M., Braspenning, J. & Denig, P., Oct-2012, In: *Pharmacoepidemiology and Drug Safety*. 21, 10, p. 1053-1059 7 p.

**A pilot qualitative study to explore stakeholder opinions regarding prescribing quality indicators**  
Martirosyan, L., Markhorst, J., Denig, P., Haaijer-Ruskamp, F. M. & Braspenning, J., 7-Jul-2012, In: *BMC Health Services Research*. 12, 12 p., 191.

**Differential effects of comorbidity on antihypertensive and glucose-regulating treatment in diabetes mellitus: a cohort study**  
Voorham, J., Haaijer-Ruskamp, F. M., Wolffenbuttel, B. H. R., de Zeeuw, D., Stolk, R. P. & Denig, P., 5-Jun-2012, In: *PLoS ONE*. 7, 6, 7 p., e38707.

**Coping with adverse drug events in patients with heart failure: Exploring the role of medication beliefs and perceptions**  
De Smedt, R. H., Jaarsma, T., Ranchor, A. V., van der Meer, K., Groenier, K. H., Haaijer-Ruskamp, F. M. & Denig, P., 2012, In: *Psychology & Health*. 27, 5, p. 570-587 18 p.

**Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis**  
de Vries, F. M., Denig, P., Pouwels, K. B., Postma, M. J. & Hak, E., 2012, In: *DRUGS*. 72, 18, p. 2365-2373 9 p.

**Self-reported adverse drug events and the role of illness perception and medication beliefs in ambulatory heart failure patients: A cross-sectional survey**  
De Smedt, R. H. E., Denig, P., van der Meer, K., Haaijer-Ruskamp, F. M. & Jaarsma, T., Dec-2011, In: *International Journal of Nursing Studies*. 48, 12, p. 1540-1550 11 p.

**A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients**  
Hakobyan, L., Haaijer-Ruskamp, F. M., de Zeeuw, D., Dobre, D. & Denig, P., 29-Sept-2011, In: *Health and Quality of Life Outcomes*. 9, 9 p., 83.

**A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timeliness**  
Sidorenkov, G., Haaijer-Ruskamp, F. M., Denig, P. & de Zeeuw, D., 8-Sept-2011, In: *PLoS ONE*. 6, 9, 8 p., 24278.

**Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review**  
Sidorenkov, G., Haaijer-Ruskamp, F. M., de Zeeuw, D., Bilo, H. & Denig, P., Jun-2011, In: *Medical Care Research and Review*. 68, 3, p. 263-289 27 p.

**Do we need individualised prescribing quality assessment? The case of diabetes treatment**  
Denig, P. & Haaijer-Ruskamp, F., Apr-2011, In: *International Journal of Clinical Pharmacy*. 33, 2, p. 145-149 5 p.

**Medication Adherence Affects Treatment Modifications in Patients With Type 2 Diabetes**  
Voorham, J., Haaijer-Ruskamp, F. M., Wolffenbuttel, B. H. R., Stolk, R. P., Denig, P. & Groningen Initiative Anal Type 2 D , Jan-2011, In: *Clinical Therapeutics*. 33, 1, p. 121-134 14 p.

**Comparing Adverse Event Rates of Oral Blood Glucose-Lowering Drugs Reported by Patients and Healthcare Providers A Post-Hoc Analysis of Observational Studies Published between 1999 and 2011**  
Hakobyan, L., Haaijer-Ruskamp, F. M., de Zeeuw, D., Dobre, D. & Denig, P., 2011, In: *Drug Safety*. 34, 12, p. 1191-1202 12 p.

**Cardiometabolic treatment decisions in patients with type 2 diabetes: the role of repeated measurements and medication burden**  
Voorham, J., Haaijer-Ruskamp, F. M., Wolffenbuttel, B. H. R., Stolk, R. P., Denig, P. & Groningen Initiative Anal Type 2 D , Oct-2010, In: *Quality & Safety in Health Care*. 19, 5, p. 411-415 5 p.

**Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study**

Voorham, J., Haaijer-Ruskamp, F. M., van der Meer, K., de Zeeuw, D., Wolffenbuttel, B. H. R., Hoogenberg, K., Denig, P. & GIANTT-Grp, Oct-2010, In: *Pharmacoepidemiology and Drug Safety*. 19, 10, p. 1078-1086 9 p.

**Methods to identify the target population: implications for prescribing quality indicators**

Martirosyan, L., Arah, O. A., Haaijer-Ruskamp, F. M., Braspenning, J. & Denig, P., 26-May-2010, In: *BMC Health Services Research*. 10, 8 p., 137.

**A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management**

Martirosyan, L., Voorham, J., Haaijer-Ruskamp, F. M., Braspenning, J., Wolffenbuttel, B. H. R. & Denig, P., Apr-2010, In: *Pharmacoepidemiology and Drug Safety*. 19, 4, p. 319-334 16 p.

**The Impact of Perceived Adverse Effects on Medication Changes in Heart Failure Patients**

De Smedt, R. H. E., Jaarsma, T., Haaijer-Ruskamp, F. M. & Denig, P., Feb-2010, In: *JOURNAL OF CARDIAC FAILURE*. 16, 2, p. 135-141 7 p.

**Kwaliteit van de behandeling van type 2-diabetes: resultaten van het GIANTT-project 2004-2007**

Voorham, J., Haaijer-Ruskamp, F. M., van der Meer, K., Wolffenbuttel, B. H. R., Hoogenberg, K., Denig, P. & de Zeeuw, D., 2010, In: *Nederlands Tijdschrift voor Geneeskunde*. 154, 4, p. A775-

**Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study**

Ab, E., Denig, P., van Vliet, T. & Dekker, J. H., 21-Apr-2009, In: *BMC Family Practice*. 10, 7 p., 24.

**Comparison of various measures for assessing medication refill adherence using prescription data**

Vink, N. M., Klungel, O. H., Stolk, R. P. & Denig, P., Feb-2009, In: *Pharmacoepidemiology and Drug Safety*. 18, 2, p. 159-165 7 p.

**Perceived medication adverse effects and coping strategies reported by chronic heart failure patients**

De Smedt, R. H. E., Denig, P., Haaijer-Ruskamp, F. M. & Jaarsma, T., Feb-2009, In: *International Journal of Clinical Practice*. 63, 2, p. 233-242 10 p.

**Voorschrijven van geneesmiddelen**

Denig, P. & Haaijer-Ruskamp, F., 2009, *Het geneesmiddel*. Buurma, H., de Jong-van den Berg, L. T. W. & Leufkens, H. G. M. (eds.). Maarssen: Elsevier Gezondheidszorg, p. 119-135

**Prescribing quality indicators of type 2 diabetes mellitus ambulatory care**

Martirosyan, L., Braspenning, J., Denig, P., de Grauw, W. J. C., Bouma, M., Storms, F. & Haaijer-Ruskamp, F. M., Oct-2008, In: *Quality & Safety in Health Care*. 17, 5, p. 318-323 6 p.

**Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetes**

Voorham, J., Haaijer-Ruskamp, F. M., Stolk, R. P., Wolffenbuttel, B. H. R., Denig, P. & GIANTT-Grp, Mar-2008, In: *Diabetes Care*. 31, 3, p. 501-503 3 p.

**Cross-sectional versus sequential quality indicators of risk factor management in patients with type 2 diabetes**

Voorham, J., Denig, P., Wolffenbuttel, B. H. R. & Haaijer-Ruskamp, F. M., Feb-2008, In: *Medical Care*. 46, 2, p. 133-141 9 p.

**Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational study**

Greving, J. P., Denig, P., de Zeeuw, D., Bilo, H. J. G. & Haaijer-Ruskamp, F. M., 20-Sept-2007, In: *Cardiovascular Diabetology*. 6, p. 25- 8 p., 25.

**Claims in advertisements for anti hypertensive drugs in a Dutch medical journal**

Greving, J. P., Denig, P., de Zeeuw, D. & Haaijer-Ruskamp, F. M., Mar-2007, In: Journal of Hypertension. 25, 3, p. 713-722 10 p.

**Computerized extraction of information on the quality of diabetes care from free text in electronic patient records of general practitioners**

Voorham, J., Denig, P. & null, null, 2007, In: Journal of the American Medical Informatics Association. 14, 3, p. 349-354 6 p.

**Consequenties van de nieuwe NHG-standaard type 2 diabetes mellitus voor de medicamenteuze bloeddruk-, (micro)albuminurie- en vetspectrumbehandeling (Zodiac-8)**

Logtenberg, S. J., Kleefstra, N., Denig, P., Houweling, S. T. & Ubink-Veltmaat, L. J., 2007, In: Nederlands Tijdschrift voor Diabetologie. 5, p. 51-57 7 p.

**An educational programme for peer review groups to improve treatment of chronic heart failure and diabetes mellitus type 2 in general practice**

Kasje, W. N., Denig, P., Stewart, R. E., de Graeff, P. A. & Haaijer-Ruskamp, F. M., Dec-2006, In: Journal of Evaluation in Clinical Practice. 12, 6, p. 613-621 9 p.

**Determinants for the adoption of angiotensin II receptor blockers by general practitioners**

Greving, J. P., Denig, P., van der Veen, W. J., Beltman, F. W., Sturkenboom, M. C. J. M. & Haaijer-Ruskamp, F. M., Dec-2006, In: Social Science & Medicine. 63, 11, p. 2890-2898 9 p.

**The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus**

Lub, R., Denig, P., van den Berg, P., Hoogenberg, K. & de Jong-van den Berg, L., Dec-2006, In: British Journal of Clinical Pharmacology. 62, 6, p. 660-665 6 p.

**Limited effect of patient and disease characteristics on compliance with hospital antimicrobial guidelines**

Mol, PGM., Denig, P., Gans, ROB., NannanPanday, PV., Degener, JE., Laseur, M. & Haaijer-Ruskamp, FM., Apr-2006, In: European Journal of Clinical Pharmacology. 62, 4, p. 297-305 9 p.

**Physicians' attitudes towards treatment guidelines: differences between teaching and nonteaching hospitals**

Greving, JP., Denig, P., de Zeeuw, D. & Haaijer-Ruskamp, FM., Feb-2006, In: European Journal of Clinical Pharmacology. 62, 2, p. 129-133 5 p.

**Uptake of angiotensin II receptor blockers in the treatment of hypertension**

Greving, JP., Denig, P., van der Veen, WJ., Beltman, FW., Sturkenboom, MCJM., de Zeeuw, D. & Haaijer-Ruskamp, FM., Jul-2005, In: European Journal of Clinical Pharmacology. 61, 5-6, p. 461-466 6 p.

**Perceived barriers for treatment of chronic heart failure in general practice; are they affecting performance?**

Kasje, W. N., Denig, P., de Graeff, P. A. & Haaijer-Ruskamp, F. M., 3-May-2005, In: BMC Family Practice. 6, 1, 7 p.

**Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel study**

Kasje, WN., Denig, P., Stewart, RE., de Graeff, PA. & Haaijer-Ruskamp, FM., Apr-2005, In: European Journal of Clinical Pharmacology. 61, 2, p. 145-151 7 p.

**Voorschrijven van geneesmiddelen**

Haaijer-Ruskamp, F. & Denig, P., 2005, *Het geneesmiddel*. Buurma, H., de Jong-van den Berg, L. T. W. & Leufkens, H. G. M. (eds.). 4e, geh. herz. dr. ed. Maarssen: Elsevier Gezondheidszorg, p. 126-143

**Does comorbidity explain trends in prescribing of newer antihypertensive agents?**

Greving, JP., Denig, P., van der Veen, WJ., Beltman, FW., Sturkenboom, MCJM., de Zeeuw, D. & Haaijer-Ruskamp, FM., Nov-2004, In: Journal of Hypertension. 22, 11, p. 2209-2215 7 p.

**Healthcare quality improvement programme improves monitoring of people with diabetes**

Denig, P., 18-Jun-2004, In: Evidence-Based Healthcare. 8, 3, p. 122-124 3 p.

**Physicians' views on joint treatment guidelines for primary and secondary care**

Kasje, WN., Denig, P., de Graeff, PA. & Haaijer-Ruskamp, FM., Jun-2004, In: International Journal for Quality in Health Care. 16, 3, p. 229-236 8 p.

**Relationship between guideline treatment and health-related quality of life in asthma**

Pont, LG., van der Molen, T., Denig, P., van der Werf, GT. & Haaijer-Ruskamp, FM., May-2004, In: European Respiratory Journal. 23, 5, p. 718-722 5 p.

**Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care**

Schaars, C. F., Denig, P., Kasje, W. N., Stewart, R. E., Wolffenbuttel, B. H. R. & Haaijer-Ruskamp, F. M., Jan-2004, In: Diabetes Care. 27, 1, p. 123-8 6 p.

**Physician, organizational, and patient factors associated with suboptimal blood pressure management in Type 2 diabetic patients in primary care**

Schaars, CF., Denig, P., Kasje, WN., Stewart, RE., Wolffenbuttel, BHR. & Haaijer-Ruskamp, FM., Jan-2004, In: Diabetes Care. 27, 1, p. 123-128 6 p.

**Validity of performance indicators for assessing prescribing quality: the case of asthma**

Pont, LG., Denig, P., van der Molen, T., van der Veen, WJ. & Haaijer-Ruskamp, FM., Jan-2004, In: European Journal of Clinical Pharmacology. 59, 11, p. 833-840 8 p.

**Prescriptieanalyse: Succes- en faalfactoren voor implementatie in de praktijk**

Denig, P., Kasje, W. N. & Haaijer-Ruskamp, F. M., 5-Dec-2003, In: Pharmaceutisch Weekblad. 138, 49, p. 1724-1728 5 p.

**Patienten in geneesmiddelenonderzoek verschillen van latere gebruikers**

Wieringa, N. F., Denig, P., de Graeff, P. A., Vos, R. & Van Der Werf, G. T., Dec-2003, In: Huisarts en Wetenschap. 46, 13, p. 85-89 5 p.

**Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000**

Pont, LG., Sturkenboom, MCJM., van Gilst, WH., Denig, P. & Haaijer-Ruskamp, FM., Jun-2003, In: Pharmacoepidemiology and Drug Safety. 12, 4, p. 327-334 8 p.

**Goede vraag verdient goede opzet**

Denig, P. & Tobi, H., 7-Mar-2003, In: Pharmaceutisch Weekblad. 138, 10, p. 327-330 4 p.

**Connecting pre-marketing clinical research and medical practice: opinion-based study of core issues and possible changes in drug regulation**

Wieringa, N. F., Peschar, J. L., Denig, P., de Graeff, P. A. & Vos, R., 2003, In: International Journal of Technology Assessment in Health Care. 19, 1, p. 202-219 18 p.

**Effect van een FTO-programma over astma op kwaliteit van leven bij patiënten. Verbetering blijft nog uit**

Denig, P., Onnes, B. & Haaijer-Ruskamp, F. M., 2003, In: Pharmaceutisch Weekblad. 138, 37, p. 1276-1281 6 p.

**Willen artsen wel (transmurale) richtlijnen? Succes- en faalfactoren voor implementatie in de praktijk.**

Denig, P., Kasje, W. N. & Haaijer-Ruskamp, F. M., 2003, In: Pharmaceutisch Weekblad. 138, 1724, p. 1728-

**Specialists' expectations regarding joint treatment guidelines for primary and secondary care**

Kasje, WN., Denig, P. & Haaijer-Ruskamp, FM., Dec-2002, In: International Journal for Quality in Health Care. 14, 6, p. 509-518 10 p.

**Clinical relevance of the gap between pre-marketing trials and medical practice: the case of the cardiovascular drugs**  
Wieringa, N. F., Denig, P., de Graeff, P. A. & Vos, R., Nov-2002, In: Netherlands Heart Journal. 10, 11, p. 441-448 8 p.

**Variations in asthma treatment in five European countries: judgement analysis of case simulations**  
Wahlström, R., Hummers-Pradier, E., Lundborg, CS., Muskova, M., Lagerlov, P., Denig, P., Oke, T., de Saintonge, DMC., Drug Educ Project Grp & Schuiling-Veninga, C., Oct-2002, In: Family practice. 19, 5, p. 452-460 9 p.

**The value of clinical judgement analysis for improving the quality of doctors' prescribing decisions**  
Denig, P., Wahlström, R., de Saintonge, MC., Haaijer-Ruskamp, F., Wahlström, R. & de Saintonge, M. C., Aug-2002, In: Medical Education. 36, 8, p. 770-780 11 p.

**Scope and nature of prescribing decisions made by general practitioners**  
Denig, P. & Witteman, CLM., Jun-2002, In: Quality & Safety in Health Care. 11, 2, p. 137-143 7 p.

**Identifying general practice patients diagnosed with asthma and their exacerbation episodes from prescribing data**  
Pont, LG., van der Werf, GT., Denig, P., Haaijer-Ruskamp, FM. & Pont, L. G., Jan-2002, In: European Journal of Clinical Pharmacology. 57, 11, p. 819-825 7 p.

**Voorschrijven van geneesmiddelen**  
Haaijer-Ruskamp, F. & Denig, P., 2002, *Het geneesmiddel*. Buurma, H., de Jong-van den Berg, L. T. W. & Leufkens, H. G. M. (eds.). Maarssen: Elsevier Gezondheidszorg, p. 124-149

**Variations in general practitioners' views of asthma management in four European countries**  
Wahlström, R., Lagerlov, P., Lundborg, CS., Veninga, CCM., Hummers-Pradier, E., Dahlgren, LO., Denig, P. & DEP Grp, Aug-2001, In: Social Science & Medicine. 53, 4, p. 507-518 12 p.

**Comparison of indicators assessing the quality of drug prescribing for asthma**  
Veninga, C. C. M., Denig, P., Pont, L. G. & Haaijer-Ruskamp, F. M., Apr-2001, In: Health services research. 36, 1, p. 143-161 19 p.

**Assessment of new cardiovascular drugs: Relationships between considerations, professional characteristics, and prescribing**  
Wieringa, NF., Denig, P., de Graeff, PA. & Vos, R., 2001, In: International Journal of Technology Assessment in Health Care. 17, 4, p. 559-570 12 p.

**Improving drug treatment in general practice**  
Veninga, CCM., Denig, P., Zwaagstra, R. & Haaijer-Ruskamp, FM., Jul-2000, In: Journal of Clinical Epidemiology. 53, 7, p. 762-772 11 p.

**Treatment of uncomplicated urinary tract infections: Exploring differences in adherence to guidelines between three European countries**  
Veninga, C. C. M., Lundborg, CS., Lagerlov, P., Hummers-Pradier, E., Denig, P. & Haaijer-Ruskamp, FM., Jan-2000, In: Annals of Pharmacotherapy. 34, 1, p. 19-26 8 p.

**Investigating decision-making by prescribers**  
Denig, P. & Haaijer-Ruskamp, F., 2000, *Handbook of drug use research methodology*. McCavock, H. (ed.). Newcastle upon Tyne: United Kingdom Drug Utilisation, Vol. 1. p. 70-87

**GPs' treatment of uncomplicated urinary tract infections: a clinical judgement analysis in four European countries**  
Hummers-Pradier, E., Denig, P., Oke, T., Lagerlov, P., Wahlström, R. & Haaijer-Ruskamp, FM., Dec-1999, In: Family practice. 16, 6, p. 605-607 3 p.

### **Evaluating an educational intervention to improve the treatment of asthma in four European countries**

Veninga, CCM., Lagerlov, P., Wahlstrom, R., Muskova, M., Denig, P., Berkhof, J., Kochen, MM., Haaijer-Ruskamp, FM. & Drug Educ Project Gr, Oct-1999, In: American Journal of Respiratory and Critical Care Medicine. 160, 4, p. 1254-1262 9 p.

### **Voorschrijven van geneesmiddelen**

Haaijer-Ruskamp, F. & Denig, P., 1999, *Het geneesmiddel*. Buurma, H., de Jong-van den Berg, L. T. W. & Leufkens, H. G. M. (eds.). 2 ed. Maarssen: Elsevier/Bunge

### **Denkbeelden van huisartsen over de behandeling van astma**

Veninga, C. C. M., Denig, P., Heyink, J. W. & Haaijer-Ruskamp, F. M., 1998, In: Huisarts en Wetenschap. 41, p. 236-240 5 p.

### **Descriptief beslistkundig onderzoek op het gebied van voorschrijfgedrag**

Denig, P. & Haaijer-Ruskamp, F. M., 1998, In: Huisarts en Wetenschap. 41, p. 274-279 6 p.

### **How doctors choose drugs**

Denig, P. & Bradley, C. P., 1998, *Prescribing in general practice*. Hobbs, R. & Bradley, C. P. (eds.). Oxford: Oxford University Press, p. 79-94

### **The decision process of the physician**

Denig, P., 1997, *Drug consumption in the Netherlands*. Bakker, A., Hekster, Y. A. & Leufkens, H. G. (eds.). Noordwijk: Amsterdam Medical Press, p. 23-36

### **DO PHYSICIANS TAKE COST INTO ACCOUNT WHEN MAKING PRESCRIBING DECISIONS**

DENIG, P. & HAAIJER-RUSKAMP, FM., Oct-1995, In: Pharmacoeconomics. 8, 4, p. 282-290 9 p.

### **Drug choice in medical practice: rationales, routines and remedies**

Denig, P., 1994, s.n.. 210 p.

### **DRUG EXPECTATIONS AND DRUG CHOICES OF HOSPITAL PHYSICIANS**

DENIG, P., HAAIJER-RUSKAMP, FM. & WESSELING, H., Aug-1993, In: Journal of Internal Medicine. 234, 2, p. 155-163 9 p.

### **TOWARDS UNDERSTANDING TREATMENT PREFERENCES OF HOSPITAL PHYSICIANS**

DENIG, P., HAAIJER-RUSKAMP, FM. & WESSELING, H., Apr-1993, In: Social Science & Medicine. 36, 7, p. 915-924 10 p.

### **THERAPEUTIC DECISION-MAKING OF PHYSICIANS**

DENIG, P. & HAAIJER-RUSKAMP, FM., 21-Feb-1992, In: Pharmaceutisch weekblad-Scientific edition. 14, 1, p. 9-15 7 p.

### **PRESCRIBING PATTERN IN A DUTCH UNIVERSITY HOSPITAL**

DENIG, P., HAAIJER-RUSKAMP, FM. & WESSELING, H., Dec-1991, In: Journal of Clinical Pharmacy and Therapeutics. 16, 6, p. 423-433 11 p.

### **IMPACT OF CLINICAL-TRIALS ON THE ADOPTION OF NEW DRUGS WITHIN A UNIVERSITY HOSPITAL**

DENIG, P., HAAIJER-RUSKAMP, FM. & WESSELING, H., 1991, In: European Journal of Clinical Pharmacology. 41, 4, p. 325-328 4 p.

### **Impact of a Drug Bulletin on the Knowledge, Perception of Drug Utility, and Prescribing Behavior of Physicians**

Denig, P., Haaijer-Ruskamp, F. M. & Zijssling, D. H., Jan-1990, In: Dicp-The annals of pharmacotherapy. 24, 1, p. 87-93 7 p.

### **HOW PHYSICIANS CHOOSE DRUGS**

DENIG, P., HAAIJER-RUSKAMP, FM. & ZIJSLING, DH., 1988, In: Social Science & Medicine. 27, 12, p. 1381-1386 6 p.



## Datasets

### **Adherence to standard-dose or low-dose statin treatment and low-density lipoprotein cholesterol response in type 2 diabetes patients**

Vries ,de, D. (Contributor), Voorham, J. (Contributor), Hak, E. (Contributor) & Denig, P. (Contributor), figshare, 25-Nov-2015

DOI: 10.6084/m9.figshare.1579453.v1,

[https://figshare.com/articles/Adherence\\_to\\_standard\\_dose\\_or\\_low\\_dose\\_statin\\_treatment\\_and\\_low\\_density\\_lipoprotein\\_cholesterol\\_response\\_in\\_type\\_2\\_diabetes\\_patients/1579453/1](https://figshare.com/articles/Adherence_to_standard_dose_or_low_dose_statin_treatment_and_low_density_lipoprotein_cholesterol_response_in_type_2_diabetes_patients/1579453/1)

### **Gender differences in adverse drug reactions: knowledge synthesis and exploration**

de Vries, S. (Contributor), Denig, P. (Contributor), Burgers, J. S. (Contributor), Kleefstra, N. (Contributor), Mol, P. G. (Contributor) & van Puijenbroek, E. (Contributor), University of Groningen, 2-Aug-2019

DOI: 10.34894/q0xnjs, <https://doi.org/10.34894%2Fq0xnjs>

### **GIANTT Groningen Initiative to ANalyze Type 2 diabetes Treatment**

Denig, P. (Creator), Universitair Medisch Centrum Groningen / Rijksuniversiteit Groningen, 1-Jan-2007

<http://www.giantt.nl> and one more link, <http://www.giantt.nl/enoutline.htm> (show fewer)

### **Quality assessment of pharmacotherapy in patients with chronic kidney disease: development of indicators**

Denig, P. (Contributor), University of Groningen, 1-Jan-2019

DOI: 10.34760/5f5b7d37ddabd

### **Quality assessment of pharmacotherapy in patients with chronic kidney disease in secondary care patients**

Denig, P. (Contributor), University of Groningen, 1-Jan-2019

DOI: 10.34760/5f5b7d5599e14, <https://doi.org/10.34760%2F5f5b7d5599e14>